Experimental eye drug targets genetic blindness

NCT ID NCT05392179

Completed Disease control Sponsor: Aldeyra Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested an experimental drug called ADX-2191 in 8 adults with retinitis pigmentosa caused by specific genetic mutations. Participants received monthly injections into one eye for up to six months. The main goal was to check safety, but researchers also looked at whether the drug could help preserve vision. Because the study is very small and early-stage, it is too soon to know if the treatment will be effective for a broader group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ADX-2191 (a drug injected into the eye monthly)
What this could lead to: If it works, this could point toward a treatment to slow vision loss in people with certain genetic forms of retinitis pigmentosa.
What could go wrong: This is a very small, early-phase trial with only 8 participants, so results may not apply to everyone. The drug is injected directly into the eye, which carries risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa retinitis pigmentosa 4

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINITIS PIGMENTOSA

Contacts and locations

Locations

Duke Eye Center

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.